Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Conclusion
Despite higher anticoagulant cost, mean overall total all-cause and AF-related cost remains comparable for patients with NVAF treated with rivaroxaban versus warfarin due to the cost offset from reduced health care resource utilization.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Atrial Fibrillation | Coumadin | Databases & Libraries | Drugs & Pharmacology | Emergency Medicine | Health | Health Management | Insurance | Statistics | Study | Warfarin